Tuesday, July 20, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)

A Conversation with the Investigators: Metastatic Castration-Resistant Prostate Cancer

A Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual Meeting

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Tuesday, July 20th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET


Emmanuel S Antonarakis, MD
Professor of Oncology and Urology
Johns Hopkins University
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Johann de Bono, MBChB, MSc, PhD
Regius Professor of Cancer Research
The Institute of Cancer Research
University of London
The Royal Marsden Hospital
London, United Kingdom

Julie N Graff, MD
Associate Professor, Hematology and Medical Oncology
OHSU Knight Cancer Institute
Portland, Oregon

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck and Sanofi Genzyme.

Current Treatment Approaches for Patients with Metastatic CRPC (mCRPC)

  • Selection and sequencing of therapies for patients with mCRPC
  • Key efficacy and safety findings from the CARD study evaluating cabazitaxel versus alternative androgen receptor (AR)-targeted therapy (abiraterone or enzalutamide) for patients with mCRPC who had received docetaxel and experienced disease progression on a prior AR-targeted agent; implications for therapeutic sequencing
  • Patient selection for radium-223 and optimal integration into mCRPC treatment algorithms
  • Ongoing evaluation of radium-223 in combination with other systemic therapies; available data from the Phase III PEACE III trial comparing enzalutamide with and without radium-223 for mCRPC
  • Incidence of BRCA1/2 mutations and other homologous recombination repair (HRR) or DNA damage response (DDR) abnormalities among patients with prostate cancer; rationale for and proposed mechanisms of antitumor activity of PARP inhibitors for metastatic prostate cancer
  • Biologic rationale for combining a PARP inhibitor with a secondary hormonal agent for patients with mCRPC harboring HRR or DDR abnormalities
  • Design, entry criteria and clinical findings from the PROfound and TRITON2 trials supporting the FDA approvals of olaparib and rucaparib, respectively, for patients with previously treated mCRPC; implications for genetic testing in clinical practice
  • Spectrum, incidence and severity of adverse events associated with olaparib compared to rucaparib; effective management strategies

Novel Agents and Strategies Under Investigation

  • Molecular mechanisms of resistance to androgen deprivation therapy in patients with prostate cancer
  • Impact of PTEN loss on metabolic reprogramming in prostate cancer; role of PTEN loss and AKT activation in prostate cancer recurrence and progression
  • Mechanistic rationale for the antitumor activity of AKT inhibitors in patients with prostate cancer and PTEN loss; design, eligibility and primary efficacy and safety results from the IPATential150 Phase III trial of ipatasertib in combination with abiraterone as first-line therapy for mCRPC
  • Biologic rationale for targeting immune checkpoints in prostate cancer; prevalence of microsatellite instability (MSI) and response to immune checkpoint blockade
  • Potential role of immune checkpoint inhibitors in therapy for MSI-high/mismatch repair-deficient or microsatellite-stable prostate cancer
  • Design, eligibility criteria and available data from ongoing Phase II and Phase III trials of immune checkpoint inhibitors alone or in combination with systemic or targeted agents for mCRPC
  • Efficacy and safety of anti-VEGF agents in patients with prostate cancer; findings from the Phase Ib COSMIC-021 trial supporting the design of the ongoing Phase III CONTACT-02 trial of cabozantinib in combination with atezolizumab for previously treated mCRPC
  • Design, eligibility criteria and key endpoints of the ongoing Phase III KEYLYNK-010 trial comparing the PARP inhibitor olaparib in combination with pembrolizumab to abiraterone or enzalutamide for patients with mCRPC who are unselected for HRR defects and have experienced failure of a next-generation hormonal agent and chemotherapy
  • Other ongoing studies with approved and investigational PARP inhibitors (eg, talazoparib, niraparib) for patients with progressive mCRPC with or without HRR or DDR aberrations (eg, TRITON3, PROpel, LuPARP, BRCAAway, COMRADE, COBRA, QUEST, MAGNITUDE)
  • Design, eligibility criteria and key endpoints of the ongoing CHAARTED2 (EA8153) trial comparing cabazitaxel with abiraterone to abiraterone alone for patients with mCRPC previously treated with docetaxel
  • Other promising novel agents and strategies currently under investigation for prostate cancer

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives

  • Apply clinical research findings in the determination of best-practice selection and sequencing of available local and systemic treatment modalities for patients with metastatic castration-resistant prostate cancer (CRPC).
  • Describe the rationale for testing patients with progressive CRPC for BRCA1/2 or related mutations, and advise individuals found to harbor these genetic abnormalities about the FDA approvals and potential benefits of PARP inhibitors.
  • Recognize the side effects associated with PARP inhibitors for prostate cancer, and develop strategies to prevent, mitigate and manage toxicities.
  • Appreciate available clinical trial data and ongoing research with immune checkpoint inhibitors alone or in combination with systemic or targeted agents for metastatic CRPC, and consider the potential roles of these strategies in clinical care.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck and Sanofi Genzyme.